Myasthenia Gravis Treatment Market
Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report, By Treatment Modality (Pharmacological Therapies, Rapid Immunotherapies, Surgical Treatment), By Route of Administration (Oral, Intravenous (IV), Subcutaneous (SC)), By End User (Hospitals, Specialty Neurology Clinics, Ambulatory Surgical Centers, Homecare Settings, Others), Forecast Period (2026–2035)
Industry Overview
Myasthenia gravis treatment market was valued at $2.2 billion in 2025 and is projected to reach $5.9 billion by 2035, expanding at a CAGR of 10.6% during 2026–2035. The market is primarily driven by the increasing adoption of targeted biologics such as FcRn inhibitors and complement inhibitors, alongside growing awareness and diagnosis rates of autoimmune neuromuscular disorders. According to the World Health Organization (WHO), rare neurological disorders, including myasthenia gravis, are increasingly recognized due to improved diagnostic infrastructure globally. Additionally, data from the U.S. Food and Drug Administration (FDA) highlights a growing number of orphan drug approvals in autoimmune diseases, supporting innovation in MG therapies. The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that over 50% of new drug pipelines in rare diseases focus on biologics, further accelerating market growth. Hospitals and specialty neurology clinics remain the primary end-users due to the need for complex treatment administration such as IVIG and plasma exchange. Meanwhile, home care settings are gaining traction due to the rise of subcutaneous therapies. Overall, the market is evolving from traditional immunosuppressants to high-value targeted therapies.
Market Dynamics
Rising Adoption of Biologics Driving Market Growth
The increasing adoption of biologics is a key growth driver in the myasthenia gravis treatment market. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), biologics account for nearly 30% of total pharmaceutical spending globally, reflecting a strong shift toward targeted therapies. In MG treatment, biologics such as FcRn inhibitors and complement inhibitors offer improved efficacy and reduced side effects compared to traditional immunosuppressants. The FDA has accelerated approvals for rare disease treatments under orphan drug designation, enabling faster commercialization of MG therapies. Companies are heavily investing in R&D, with multiple late-stage pipeline drugs targeting specific antibodies associated with MG. Between 2025 and 2026, major players have expanded clinical trials and launched advanced biologics, enhancing patient outcomes. Additionally, the IQVIA Institute reports that global spending on rare disease treatments is growing at over 10% annually, supporting increased demand for MG therapies. These trends collectively contribute to sustained market expansion.
High Treatment Costs and Limited Accessibility Restraining Market Growth
Despite strong growth, the market faces significant challenges due to high treatment costs and limited accessibility. Biologic therapies for MG can cost upwards of $200,000 annually per patient, creating financial barriers, especially in developing regions. According to the OECD, healthcare expenditure disparities across countries limit access to advanced therapies in low- and middle-income economies.
Supply chain constraints also impact the availability of plasma-derived products such as IVIG. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights that plasma collection and processing are resource-intensive, leading to supply shortages during high-demand periods. Moreover, reimbursement challenges and regulatory complexities hinder market penetration. To address these issues, companies are focusing on cost optimization, biosimilar development, and expanding manufacturing capacities. However, affordability remains a critical barrier to widespread adoption.
Market Segmentation
- Based on the treatment modality, the market is segmented into pharmacological therapies, rapid immunotherapies, and surgical treatment.
- Based on the route of administration, the market is segmented into oral, intravenous (IV), and subcutaneous (SC).
- Based on the end user, the market is segmented into hospitals, specialty neurology clinics, ambulatory surgical centers, home care settings, and others.
Pharmacological Therapies Segment Leads the Market
The pharmacological therapies segment dominates the myasthenia gravis treatment market due to the widespread use of biologics and immunosuppressants. High-cost biologics such as complement inhibitors and FcRn inhibitors contribute significantly to revenue generation. These therapies are widely adopted in hospitals and specialty clinics due to their targeted mechanism of action. Between 2022 and 2026, pharmaceutical companies have focused on expanding their biologics portfolios, improving treatment outcomes, and reducing disease progression. The increasing prevalence of generalized MG and rising diagnosis rates further support demand for pharmacological therapies. Additionally, favorable regulatory pathways for orphan drugs have accelerated product approvals, strengthening the segment’s leadership position.
Subcutaneous (SC) Segment to Record Strong Growth
The subcutaneous (SC) segment is expected to witness the fastest growth during the forecast period due to its convenience and suitability for home care settings. SC therapies reduce the need for hospital visits, improving patient compliance and lowering healthcare costs. Technological advancements in drug delivery systems have enabled the development of self-administered biologics, driving adoption. According to the International Telecommunication Union (ITU), digital health integration is enhancing remote patient monitoring, further supporting home-based treatments. Investments in patient-centric care models and decentralized healthcare infrastructure are accelerating the growth of SC therapies. Pharmaceutical companies are increasingly focusing on developing SC formulations of existing biologics, contributing to rapid segment expansion.
Regional Outlook
The global myasthenia gravis treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the myasthenia gravis treatment market due to advanced healthcare infrastructure and high adoption of biologics. According to the FDA, the U.S. accounts for the majority of orphan drug approvals globally, supporting innovation in rare disease treatments. The PhRMA reports that U.S. pharmaceutical companies invest over $850 billion annually in R&D, driving the development of advanced MG therapies. Additionally, strong reimbursement frameworks and widespread access to specialty care contribute to market growth. The presence of leading pharmaceutical companies further strengthens the country’s position as a global leader.
China to Record Strong Growth
China is expected to witness the fastest growth due to expanding healthcare infrastructure and increasing investments in biotechnology. According to the OECD, China’s healthcare expenditure has been growing steadily, supporting improved access to advanced treatments. The International Trade Centre (ITC) highlights rising pharmaceutical imports and domestic production capabilities, indicating strong market potential. Government initiatives to promote rare disease awareness and improve diagnosis rates are further driving demand. Additionally, the expansion of local manufacturing facilities and partnerships with global companies is accelerating market growth.
Market Player Outlook
The myasthenia gravis treatment market is highly competitive, characterized by the presence of major pharmaceutical companies focusing on biologics and plasma-derived therapies. Companies are investing heavily in R&D, strategic collaborations, and product launches to strengthen their market positions. The key players, such as UCB S.A., AstraZeneca (Alexion Pharmaceuticals), Takeda Pharmaceutical Company, Argenx SE, and CSL Limited (CSL Behring), dominate the market. These companies leverage advanced technologies, strong distribution networks, and robust product portfolios to maintain a competitive advantage. The market is witnessing a shift toward targeted therapies, with companies focusing on innovation and patient-centric solutions.
Recent Developments
- In March 2024, AstraZeneca (through Alexion) has strengthened its presence in the Myasthenia Gravis treatment market with the continued expansion of ULTOMIRIS, a long-acting C5 complement inhibitor approved for generalized myasthenia gravis (gMG). Recent regulatory approval in the US for NMOSD, supported by strong Phase III trial outcomes showing near-complete relapse reduction, reinforces its clinical efficacy and broad immunology potential.
- In October 2023, UCB strengthened its position in the myasthenia gravis treatment market with the US FDA approval of ZILBRYSQ (zilucoplan), a first-in-class once-daily, self-administered C5 complement inhibitor for generalized myasthenia gravis (gMG). The approval, supported by strong Phase 3 RAISE study results, highlights significant clinical efficacy and patient convenience.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global myasthenia gravis treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Myasthenia Gravis Treatment Market Sales Analysis – Treatment Modality | Route of Administration | End User ($ Million)
- Myasthenia Gravis Treatment Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Myasthenia Gravis Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Myasthenia Gravis Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Myasthenia Gravis Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Myasthenia Gravis Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Myasthenia Gravis Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Myasthenia Gravis Treatment Market Revenue and Share by Manufacturers
- Myasthenia Gravis Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 UCB S.A.
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 AstraZeneca (Alexion Pharmaceuticals)
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Takeda Pharmaceutical Company
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Argenx SE
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 CSL Limited (CSL Behring)
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership and Collaboration
- Global Myasthenia Gravis Treatment Market Sales Analysis by Treatment Modality ($ Million)
5.1 Pharmacological Therapies
5.2 Rapid Immunotherapies
5.3 Surgical Treatment
- Global Myasthenia Gravis Treatment Market Sales Analysis by Route of Administration ($ Million)
6.1 Oral
6.2 Intravenous (IV)
6.3 Subcutaneous (SC)
- Global Myasthenia Gravis Treatment Market Sales Analysis by End User ($ Million)
7.1 Hospitals
7.2 Specialty Neurology Clinics
7.3 Ambulatory Surgical Centers
7.4 Homecare Settings
7.5 Others
- Regional Analysis
8.1 North American Myasthenia Gravis Treatment Market Sales Analysis – Treatment Modality | Route of Administration | End User | Country ($ Million)
8.1.1 United States
8.1.2 Canada
8.2 European Myasthenia Gravis Treatment Market Sales Analysis – Treatment Modality | Route of Administration | End User | Country ($ Million)
8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe
8.3 Asia-Pacific Myasthenia Gravis Treatment Market Sales Analysis – Treatment Modality | Route of Administration | End User | Country ($ Million)
8.3.1 China
8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific
8.4 Rest of the World Myasthenia Gravis Treatment Market Sales Analysis – Treatment Modality | Route of Administration | End User | Country ($ Million)
8.4.1 Latin America
8.4.2 Middle East and Africa
- Company Profiles
9.1 Amgen (Horizon Therapeutics)
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.2 Astellas Pharma
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.3 Bausch Health (Bausch + Lomb)
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.4 Biotest AG
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.5 Bristol Myers Squibb (BMS)
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.6 Grifols, S.A.
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies
9.7 Hansa Biopharma
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.8 Johnson & Johnson (Janssen)
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.9 Kedrion Biopharma
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.10 LFB Group
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.11 Merck & Co. (MSD)
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies
9.12 Mitsubishi Tanabe Pharma
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.13 Novartis AG (Sandoz)
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.14 Octapharma AG
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.15 Pfizer Inc.
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.16 Regeneron Pharmaceuticals
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.17 Roche (Chugai Pharmaceutical)
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.18 Sanofi S.A.
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.19 Zai Lab
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
1. Global Myasthenia Gravis Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
2. Global Pharmacological Therapies for Myasthenia Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Rapid Immunotherapies for Myasthenia Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Surgical Treatment for Myasthenia Gravis Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Myasthenia Gravis for Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
6. Global Oral Myasthenia for Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Intravenous (IV) for Myasthenia Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Subcutaneous (SC) for Myasthenia Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Myasthenia Gravis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
10. Global Myasthenia Gravis Treatment for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Myasthenia Gravis Treatment for Specialty Neurology Clinics Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Myasthenia Gravis Treatment for Ambulatory Surgical Centers Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Myasthenia Gravis Treatment for Homecare Settings Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Myasthenia Gravis Treatment for Others Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Myasthenia Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
16. North America Myasthenia Gravis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
17. North America Myasthenia Gravis Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
18. North America Myasthenia Gravis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
19. North America Myasthenia Gravis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
20. Europe Myasthenia Gravis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
21. Europe Myasthenia Gravis Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
22. Europe Myasthenia Gravis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
23. Europe Myasthenia Gravis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
24. Asia-Pacific Myasthenia Gravis Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
25. Asia-Pacific Myasthenia Gravis Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
26. Asia-Pacific Myasthenia Gravis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
27. Asia-Pacific Myasthenia Gravis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
28. Rest of the World Myasthenia Gravis Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
29. Rest of the World Myasthenia Gravis Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
30. Rest of the World Myasthenia Gravis Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
31. Rest of the World Myasthenia Gravis Treatment Market Research and Analysis by End User, 2025–2035 ($ Million)
1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE BY END-USER, 2019 VS 2026 (%)
3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
4. THE US MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
5. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
6. UK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
7. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
8. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
9. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
10. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
11. ROE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
12. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
13. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
14. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF THE WORLD MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
- Printable version
- No restriction to number of users within the company
